{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:58:41Z","timestamp":1789595921078,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40262-018-0695-9","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T05:25:10Z","timestamp":1531200310000},"page":"283-297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis"],"prefix":"10.1007","volume":"58","author":[{"given":"Robert","family":"Hermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Novakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Terranova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Fluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Munafo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"issue":"Suppl 1","key":"695_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9(Suppl 1):S5\u201348.","journal-title":"Mult Scler Relat Disord."},{"issue":"9648","key":"695_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u201317.","journal-title":"Lancet"},{"issue":"5","key":"695_CR3","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326.","journal-title":"N Engl J Med"},{"key":"695_CR4","doi-asserted-by":"publisher","unstructured":"Giovannoni G, Soelberg-Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. Safety and efficacy of Cladribine Tablets in patients with relapsing\u2013remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. \nhttps:\/\/doi.org\/10.1177\/1352458517727603\n\n(Epub 1 Aug 2017).","DOI":"10.1177\/1352458517727603"},{"issue":"3","key":"695_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","volume":"13","author":"TP Leist","year":"2014","unstructured":"Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13(3):257\u201367.","journal-title":"Lancet Neurol."},{"key":"695_CR6","unstructured":"Merck Serono Australia Pty Ltd. MAVENCLAD\u00ae Tablets: Product Information. 2017 [11 Jan 18]. \nhttps:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2010-PI-07339-3\n\n."},{"key":"695_CR7","unstructured":"Merck Serono Europe Limited. MAVENCLAD 10\u00a0mg tablets: summary of product characteristics. 2017. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004230\/WC500234561.pdf\n\n."},{"key":"695_CR8","unstructured":"EMD Serono. MAVENCLAD Cladribine 10\u00a0mg Tablet: Product Monograph. 2017 [12\/12\/17]. \nhttps:\/\/pdf.hres.ca\/dpd_pm\/00042413.PDF\n\n."},{"key":"695_CR9","doi-asserted-by":"crossref","unstructured":"Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19(1 Suppl A):S24\u201340.","DOI":"10.18553\/jmcp.2013.19.s1.S24"},{"issue":"8825","key":"695_CR10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","volume":"340","author":"E Beutler","year":"1992","unstructured":"Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet. 1992;340(8825):952\u20136.","journal-title":"Lancet"},{"issue":"1","key":"695_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1517\/14656566.2013.754012","volume":"14","author":"G Comi","year":"2013","unstructured":"Comi G, Hartung HP, Kurukulasuriya NC, Greenberg SJ, Scaramozza M. Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Pharmacother. 2013;14(1):123\u201336.","journal-title":"Expert Opin Pharmacother"},{"key":"695_CR12","first-page":"S74","volume":"15","author":"C Salvat","year":"2009","unstructured":"Salvat C, Curchod M, Guedj E, Peixoto H, Guerrier M, Wojcik J, et al. Cellular expression profiling of genes involved in the cladribine metabolic pathway: insights into mechanism of action in multiple sclerosis. Mult Scler. 2009;15:S74\u20135.","journal-title":"Mult Scler."},{"issue":"S3","key":"695_CR13","first-page":"598","volume":"23","author":"P Soelberg-Sorensen","year":"2017","unstructured":"Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G. P1141: innate immune cell counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with Cladribine Tablets 3.5\u00a0mg\/kg in CLARITY and CLARITY extension. Mult Scler. 2017;23(S3):598.","journal-title":"Mult Scler."},{"issue":"3","key":"695_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","volume":"31","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr Opin Neurol. 2018;31(3):233\u201343.","journal-title":"Curr Opin Neurol"},{"key":"695_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrneurol.2017.119","volume":"13","author":"H Wiendl","year":"2017","unstructured":"Wiendl H. Cladribine: an old newcomer for pulsed immune reconstitution in MS. Nat Rev Neurol. 2017;13:573\u20134.","journal-title":"Nat Rev Neurol."},{"key":"695_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2210-5-4","volume":"5","author":"S Lindemalm","year":"2005","unstructured":"Lindemalm S, Savic RM, Karlsson MO, Juliusson G, Liliemark J, Albertioni F. Application of population pharmacokinetics to cladribine. BMC Pharmacol. 2005;5:4.","journal-title":"BMC Pharmacol"},{"key":"695_CR17","unstructured":"Janssen-Cilag Ltd. Leustat injection: summary of product characteristics. 2014."},{"issue":"2","key":"695_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","volume":"32","author":"J Liliemark","year":"1997","unstructured":"Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet. 1997;32(2):120\u201331.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"695_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s40262-017-0516-6","volume":"56","author":"RM Savic","year":"2017","unstructured":"Savic RM, Novakovic AM, Ekblom M, Munafo A, Karlsson MO. Population pharmacokinetics of cladribine in patients with multiple sclerosis. Clin Pharmacokinet. 2017;56(10):1245\u201353.","journal-title":"Clin Pharmacokinet"},{"key":"695_CR20","unstructured":"European Medicines Agency. European Public Assessment Report: Mavenclad. European Medicines Agency; 2017."},{"key":"695_CR21","unstructured":"Munafo A, Tran D, Marcus S, Ammoury N. An open-label randomized three-way crossover study on the absolute oral bioavailability of Cladribine Tablets administered to subjects with multiple sclerosis. Poster presented at the 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 10th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis; 2005."},{"key":"695_CR22","unstructured":"Merck Serono Europe Limited. MAVENCLAD 10\u00a0mg tablets: summary of product characteristics. 2017 [13\/09\/17]. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004230\/WC500234561.pdf\n\n."},{"issue":"12","key":"695_CR23","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1080\/15257770.2011.597372","volume":"30","author":"PX Fernandez-Calotti","year":"2011","unstructured":"Fernandez-Calotti PX, Colomer D, Pastor-Anglada M. Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies. Nucleos Nucleot Nucl. 2011;30(12):1324\u201340.","journal-title":"Nucleos Nucleot Nucl."},{"issue":"3","key":"695_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/sj.leu.2403271","volume":"18","author":"M Pastor-Anglada","year":"2004","unstructured":"Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia. 2004;18(3):385\u201393.","journal-title":"Leukemia"},{"issue":"1","key":"695_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/sj.leu.2401633","volume":"14","author":"AMP Wright","year":"2000","unstructured":"Wright AMP, Gati WP, Paterson ARP. Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport. Leukemia. 2000;14(1):52\u201360.","journal-title":"Leukemia"},{"issue":"14","key":"695_CR26","doi-asserted-by":"publisher","first-page":"6965","DOI":"10.1158\/0008-5472.CAN-06-4720","volume":"67","author":"K Takenaka","year":"2007","unstructured":"Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, et al. Substrate overlap between Mrp4 and Abcg2\/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res. 2007;67(14):6965\u201372.","journal-title":"Cancer Res"},{"issue":"1","key":"695_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejps.2003.07.003","volume":"21","author":"LMS Chan","year":"2004","unstructured":"Chan LMS, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci. 2004;21(1):25\u201351.","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"695_CR28","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1158\/1535-7163.MCT-08-0427","volume":"7","author":"C de Wolf","year":"2008","unstructured":"de Wolf C, Jansen R, Yamaguchi H, de Haas M, de Wetering KV, Wijnholds J, et al. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008;7(9):3092\u2013102.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"695_CR29","first-page":"1235","volume":"54","author":"CM Kearns","year":"1994","unstructured":"Kearns CM, Blakley RL, Santana VM, Crom WR. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res. 1994;54(5):1235\u20139.","journal-title":"Cancer Res"},{"issue":"12","key":"695_CR30","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3109\/00498254.2013.791762","volume":"43","author":"H Scheible","year":"2013","unstructured":"Scheible H, Laisney M, Wimmer E, Javornik A, Dolgos H. Comparison of the in vitro and in vivo metabolism of Cladribine (Leustatin, Movectro) in animals and human. Xenobiotica. 2013;43(12):1084\u201394.","journal-title":"Xenobiotica"},{"issue":"3","key":"695_CR31","first-page":"653","volume":"4","author":"F Albertioni","year":"1998","unstructured":"Albertioni F, Lindemalm S, Reichelova V, Pettersson B, Eriksson S, Juliusson G, et al. Pharmacokinetics of cladribine in plasma and its 5\u02b9-monophosphate and 5\u02b9-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res. 1998;4(3):653\u20138.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"695_CR32","doi-asserted-by":"publisher","first-page":"F1439","DOI":"10.1152\/ajprenal.90411.2008","volume":"296","author":"AN Elwi","year":"2009","unstructured":"Elwi AN, Damaraju VL, Kuzma ML, Mowles DA, Baldwin SA, Young JD, et al. Transepithelial fluxes of adenosine and 2\u2032-deoxyadenosine across human renal proximal tubule cells: roles of nucleoside transporters hENT1, hENT2, and hCNT3. Am J Physiol Renal Physiol. 2009;296(6):F1439\u201351.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"695_CR33","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1200\/JCO.1996.14.3.978","volume":"14","author":"A Saven","year":"1996","unstructured":"Saven A, Cheung WK, Smith I, Moyer M, Johannsen T, Rose E, et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol. 1996;14(3):978\u201383.","journal-title":"J Clin Oncol"},{"key":"695_CR34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002481","author":"RA Marrie","year":"2016","unstructured":"Marrie RA, Patten SB, Tremlett H, Wolfson C, Warren S, Svenson LW, et al. Sex differences in comorbidity at diagnosis of multiple sclerosis: a population-based study. Neurology. 2016. \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000002481\n\n. (Epub 9 Mar  2016).","journal-title":"Neurology."},{"key":"695_CR35","unstructured":"University of Washington. Drug interaction database program. 2017 [08\/11\/2017]. \nhttps:\/\/www.druginteractioninfo.org\/\n\n."},{"issue":"1","key":"695_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1365-2141.2008.07432.x","volume":"144","author":"H Chtioui","year":"2009","unstructured":"Chtioui H, Millius C, Lammle B, Lauterburg BH. Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation. Br J Haematol. 2009;144(1):136\u20137.","journal-title":"Br J Haematol."},{"issue":"1","key":"695_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/0091270007307881","volume":"48","author":"CE Garnett","year":"2008","unstructured":"Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008;48(1):13\u20138.","journal-title":"J Clin Pharmacol"},{"key":"695_CR38","doi-asserted-by":"crossref","unstructured":"Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G. Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with Cladribine Tablets 3.5\u00a0mg\/kg in CLARITY and CLARITY Extension (P5.379). Neurology. 2017;88(16):P5.379.","DOI":"10.26226\/morressier.59a3edabd462b8028d895161"},{"key":"695_CR39","doi-asserted-by":"publisher","unstructured":"Novakovic AM, Thorsted A, Schindler E, J\u00f6nsson S, Munafo A, Karlsson MO. Pharmacometric Analysis of the relationship between absolute lymphocyte count and expanded Disability Status Scale and relapse rate, efficacy end points, in Multiple Sclerosis Trials. J Clin Pharmacol. \nhttps:\/\/doi.org\/10.1002\/jcph.1136\n\n(Epub 10 May 2018).","DOI":"10.1002\/jcph.1136"},{"issue":"11","key":"695_CR40","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple-sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444\u201352.","journal-title":"Neurology."},{"issue":"1","key":"695_CR41","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1208\/s12248-016-9977-z","volume":"19","author":"AM Novakovic","year":"2017","unstructured":"Novakovic AM, Krekels EHJ, Munafo A, Ueckert S, Karlsson MO. Application of item response theory to modeling of Expanded Disability Status Scale in multiple sclerosis. AAPS J. 2017;19(1):172\u20139.","journal-title":"AAPS J"},{"key":"695_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0693-y","author":"N Terranova","year":"2018","unstructured":"Terranova N, Hicking C, Dangond F, Munafo A. Effects of postponing treatment in the second year of cladribine administration: clinical trial simulation analysis of absolute lymphocyte counts and relapse rate in patients with relapsing-remitting multiple sclerosis (RRMS). Clin Pharmacokinet. 2018. \nhttps:\/\/doi.org\/10.1007\/s40262-018-0693-y\n\n.","journal-title":"Clin Pharmacokinet."}],"updated-by":[{"DOI":"10.1007\/s40262-018-0706-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000}}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-0695-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0695-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0695-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T13:46:06Z","timestamp":1595857566000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-0695-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-0695-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40262-018-0706-x","asserted-by":"object"}]},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"assertion":[{"value":"10 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The cladribine prodrug is phosphorylated intracellularly to its active product, 2-chlorodeoxyadenosine triphosphate (Cd-ATP), by deoxycytidine kinase.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The studies summarised in this report were sponsored by EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany (in the US), and Merck Serono SA, Geneva, an affiliate of Merck KGaA, Darmstadt, Germany (rest of the world). Medical writing assistance was funded by Merck KGaA, Darmstadt, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Robert Hermann served as an external clinical pharmacology expert advisor for various aspects of several cladribine studies, and received financial support for research, consulting and training services from Merck KGaA, Darmstadt, Germany. Mats Karlsson is an employee of Uppsala University, which has performed contractual research for Merck KGaA, Darmstadt, Germany. Ana Novakovic and Markus Fluck are employees of Merck KGaA, Darmstadt, Germany, and Nadia Terranova and Alain Munafo are employees of Merck Serono SA, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}